দেশ: আয়ার্লণ্ড
ভাষা: ইংরেজি
সূত্র: HPRA (Health Products Regulatory Authority)
OXALIPLATIN
Fresenius Kabi Oncology Plc
OXALIPLATIN
5 Mg/Ml
Pdr for Soln for Infusion
Product subject to prescription which may not be renewed (A)
Withdrawn
2014-05-30
[ V inod Pal ] D:\FK-DA TA\Europe\Oxaliplatin\L YO\IRL\Draft\Oxaliplatin - L YO - Pack Insert - IRL.indd XXXXXXXXXX XXXXXX V001 Dimension: 270 x 320 mm Last Modified: 22 February 2013 12:06 PM Ver. 04 Black OXALIPLATIN - LYO - PACK INSERT - IRL The following information is intended for healthcare professionals only: INSTRUCTIONS FOR USE, HANDLING AND DISPOSAL As with other potentially toxic compounds, caution should be exercised when handling and preparing oxaliplatin solutions. INSTRUCTIONS FOR HANDLING The handling of this cytotoxic agent by healthcare personnel requires every precaution to guarantee the protection of the handler and his surroundings. The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicines used, in conditions that guarantee the integrity of the medicinal product, the protection of the environment and in particular the protect ion of the personnel handling the medicines, in accordance with the hospital policy . It requires a preparation area reserved for this purpose. It is forbidden to smoke, eat or drink in this area. Personnel must be provided with appropriate handling materials, notably long sleeve d gowns, protectio n masks, caps, protective goggles, sterile single-use gloves, protective covers for the work area, containers and collection bags for waste. Excreta and vomit must be handled with care. Pregnant women must be warned to avoid handling cytotoxic agents. Any broken container must be treated with the same precautions and considered as conta minated waste. Contaminated waste should be incinerated in suitably labelled rigid containers. See below chapter “Disposal”. If সম্পূর্ণ নথি পড়ুন
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Oxaliplatin 5 mg/ml powder for solution for infusion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of reconstituted solution for infusion contains 5 mg of oxaliplatin. 50 mg vial: each vial contains 50 mg of oxaliplatin for reconstitution in 10 ml of solvent. 100 mg vial: each vial contains 100 mg of oxaliplatin for reconstitution in 20 ml of solvent. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Powder for solution for infusion. White to grey-white (clumped) powder. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Oxaliplatin in combination with 5-fluorouracil (5FU) and folinic acid (FA) is indicated for: • Adjuvant treatment of stage III (Duke's C) colon cancer after complete resection of primary tumor • Treatment of metastatic colorectal cancer. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION The preparation of injectable solutions of cytotoxic agents must be carried out by trained specialist personnel with knowledge of the medicinal product used, in conditions that guarantee the integrity of the medicinal product, the protection of the environment and in particular the protection of the personnel handling the medicinal products, in accordance with hospital policy. It requires a preparation area reserved for this purpose. It is forbidden to smoke, eat or drink in this area. (see section 6.6) Posology FOR ADULTS ONLY The recommended dose for oxaliplatin in adjuvant setting is 85 mg/m² intravenously repeated every two weeks for 12 cycles (6 months). The recommended dose for oxaliplatin in treatment of metastatic colorectal cancer is 85 mg/m² intravenously repeated every 2 weeks or until disease progression or unacceptable toxicity. Dosage given should be adjusted according to সম্পূর্ণ নথি পড়ুন